Aiforia changes CFO
By Antti Luiro
Summary
- Aiforia has appointed Antti Ojala as the new CFO, effective by March 2, 2026, succeeding Veli-Matti Parkkonen, who will remain until March 31, 2026, to ensure a smooth transition.
- Ojala brings extensive experience in financial management within the health technology sector, having previously served as CFO at Aurevia Oy and Mobidiag Oy, which is seen as beneficial for Aiforia's growth strategy.
- The company recently raised 4.2 MEUR through a directed share issue, with cash expected to last until Q4 2026, highlighting the importance of Ojala's expertise in financing arrangements for future growth.
- The announcement does not affect current financial estimates or operations, as the transition is controlled and planned to be seamless.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 12/23/2025 at 8:40 am EET.
Aiforia announced on Monday that it has appointed Antti Ojala as the company's new CFO and a member of the management team. In our view, Ojala seems to be a very suitable choice for Aiforia's CFO due to his long experience in the health technology sector and financial management. The news has no impact on our estimates.
The new CFO has a strong background in health technology
Antti Ojala is transferring to Aiforia from Aurevia Oy, where he served as CFO and was responsible for financial operations. Ojala has previous experience in financial management from health technology and diagnostics companies such as Mobidiag Oy. We consider Ojala's industry knowledge and experience with growth companies to be a valuable addition to Aiforia's management team. The press release highlighted Ojala's experience in leading strategic projects and investor relations, as well as his use of various financing instruments.
We consider financial expertise crucial in Aiforia's current development phase. The company raised 4.2 MEUR in gross proceeds through a directed share issue in December, and we estimate that the current cash will be sufficient until approximately Q4 2026. We have predicted that the company will need additional financing to implement its growth strategy in the coming years, so the new CFO's experience with various financing arrangements is important for the company.
During the tenure of the current CFO, Veli-Matti Parkkonen, Aiforia has successfully completed an IPO and an IFRS transition, and has raised additional funding through share issues. Ojala will start in his position by March 2, 2026, at the latest. Current CFO Veli-Matti Parkkonen will leave the company but will remain until March 31, 2026, to ensure a smooth handover of duties. The change appears controlled, and the transition period allows for a smooth handover. In our view, the news has no immediate impact on Aiforia's operations or our financial forecasts.
Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.
Read more on company pageKey Estimate Figures19.11.2025
| 2024 | 25e | 26e | |
|---|---|---|---|
| Revenue | 2.9 | 3.3 | 5.1 |
| growth-% | 18.9 % | 16.4 % | 55.0 % |
| EBIT (adj.) | -12.2 | -10.9 | -8.6 |
| EBIT-% (adj.) | -427.8 % | -328.4 % | -167.6 % |
| EPS (adj.) | -0.41 | -0.39 | -0.28 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | neg. | neg. | neg. |
| EV/EBITDA | neg. | neg. | neg. |
Forum discussions
